Celularity Inc. (CELU)
NASDAQ: CELU · Real-Time Price · USD
0.4831
-0.0880 (-15.41%)
At close: Nov 18, 2026, 4:00 PM EST
0.5001
+0.0170 (3.52%)
Pre-market: Nov 19, 2026, 7:07 AM EST
Celularity Revenue
Celularity had revenue of $5.43M in the quarter ending June 30, 2026, a decrease of -5.30%. This brings the company's total for the last twelve months to $18.67M, down -58.14% year-over-year. In the year 2025, Celularity had annual revenue of $26.55M, down -51.03%. That makes Celularity the 34,296th largest company in the world by revenue and 4,499th in the United States.
Revenue (ttm)
$18.67M
Revenue Growth
-58.14%
P/S Ratio
0.84
Revenue / Employee
$162,313
Employees
115
Market Cap
15.68M
Revenue by Segment
- Degenerative Disease 17.31M 65.2%
- Biobanking 5.43M 20.5%
- Cell Therapy 3.81M 14.3%
Fiscal year ended Dec 31, 2025 See the full Celularity breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 26.55M | -27.67M | -51.03% |
| Dec 31, 2024 | 54.22M | 31.45M | 138.11% |
| Dec 31, 2023 | 22.77M | 4.80M | 26.68% |
| Dec 31, 2022 | 17.98M | -3.36M | -15.75% |
| Dec 31, 2021 | 21.34M | 7.06M | 49.43% |
| Dec 31, 2020 | 14.28M | - | - |
| Dec 31, 2019 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BioStem Technologies | 31.75M |
| Lipocine | 3.74M |
| Marker Therapeutics | 2.31M |
| Seres Therapeutics | 2.13M |
| Fractyl Health | 3.00K |
CELU News
- 6 days ago - Vesalius Longevity Labs Appoints Harvey Spevak as Chairman to Accelerate Global Growth and Brand Development - Newsfile Corp
- 9 days ago - Celularity Proxy statement: Proxy filing - Filings
- 9 days ago - Celularity Proxy statement: Proxy filing - Filings
- 20 days ago - Celularity, Vesalius Longevity Labs signs exclusive collaboration for Peptual - TheFly
- 20 days ago - Celularity and Vesalius Longevity Labs Sign Exclusive Collaboration for Peptual® Peptide APIs Manufactured in the United States - Business Wire
- 21 days ago - Celularity Proxy statement: Proxy filing - Filings
- 4 weeks ago - Celularity Regains Compliance with Nasdaq Periodic Reporting Requirement - GlobeNewsWire
- 4 weeks ago - Celularity Quarterly report: Q2 2026 - Filings